BMD42-2910, a Novel Benzoxazole Derivative, Shows a Potent Anti-prion Activity and Prolongs the Mean Survival in an Animal Model of Prion Disease

Prion diseases are a group of neurodegenerative and fatal central nervous system disorders. The pathogenic mechanism involves the conversion of cellular prion protein (PrP ) to an altered scrapie isoform (PrP ), which accumulates in amyloid deposits in the brain. However, no therapeutic drugs have demonstrated efficacy in clinical trials. We previously reported that BMD42-29, a synthetic compound discovered , is a novel anti-prion compound that inhibits the conversion of PrP to protease K (PK)-resistant PrP fragments (PrP ). In the present study, 14 derivatives of BMD42-29 were obtained from BMD42-29 by modifying in the side chain by feedback, with the aim to determine whether they improve anti-prion activity. These derivatives were assessed in a PrP -infected cell model and some derivatives were further tested using real timequaking induced conversion (RT-QuIC). Among them, BMD42-2910 showed high anti-prion activity at low concentrations and also no toxic effects in a mouse model. Interestingly, abundant PrP was reduced in brains of mice infected with prion strain when treated with BMD42- 2910, and the mice survived longer than control mice and even that treated with BMD42-29. Finally, high binding affinity was predicted in the virtual binding sites (Asn159, Gln 160, Lys194, and Glu196) when PrP was combined with BMD-42-2910. Our findings showed that BMD42-2910 sufficiently reduces PrP generation and in vivo and may be a promising novel anti-prion compound.